Wall Street Titan
Contributor since: 2011
Articles
Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Thu, Aug. 4 ALDX13 Comments
Athersys Shares Are Ready To Rumble Following Period Of Turmoil
Top IdeaAug. 30, 2021 ATHX91 Comments
AVITA Medical Gains FDA Expanded Labels In 'Better Mousetrap' Burn Treatment
Jun. 11, 2021 RCEL16 Comments
Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
Jun. 1, 2021 ALDX44 Comments
Update On Athersys - Trying To Read Between The Lines
Feb. 3, 2021 ATHX63 Comments
Marketplace Contributors 2021 Top Ideas - Part 2
Feb. 2, 2021 ABUS, AMT, AVHHL31 Comments
2021 Roundtable: General Outlook - Biotech And Healthcare Investing
Jan. 11, 2021 ETNB, KPTI, MRTX3 Comments
2021 Roundtable: Vaccine News - Biotech, Tech, Growth, And Energy Stock Analysis
Dec. 22, 2020 31 Comments
Mesoblast Needs A Solution To MSC Scalability Issues - Cynata Therapeutics Has An Answer
Oct. 9, 2020 CYYNF, MESO35 Comments
ThermoGenesis Holdings: Many Short-Term Catalysts In Low-Float Stock
Jul. 20, 2020 THMO20 Comments
5 Stem Cell Companies Racing Towards COVID-19 ARDS Therapy
May 7, 2020 ATHX, CAPR, CYYNF170 Comments
Athersys Sees 4 Million Share Insider Buy From Partner Running COVID-19 ARDS Trial In Japan
Mar. 30, 2020 ATHX107 Comments
Athersys - Now In Play For COVID-19 - FDA Fast Tracked Therapy For ARDS
Mar. 18, 2020 ATHX87 Comments
Avita Medical Enters 2020 With Great Momentum
Editors' PickJan. 9, 2020 RCEL76 Comments
Biotech In 2020: M&A And Gene Therapy In Focus
Editors' PickDec. 27, 2019 RCKT, AMRN, MYOV116 Comments
The Reincarnation Of ThermoGenesis With A Better Mousetrap For CAR-T Manufacturing
Dec. 23, 2019 THMO43 Comments
The Stem Cell Triple Play Revisited
Sep. 23, 2019 ATHX, RCEL, CYYNF36 Comments
The Stem Cell Triple Play: 3 Companies With Great Value Drivers
Editors' PickJun. 14, 2019 ATHX, RCEL, CYYNF113 Comments
Avita Medical: A Better Mousetrap With FDA Approval To Treat Patient Burns
Feb. 12, 2019 RCEL, AVHHL111 Comments
Keeping Focused Amidst The Biotech Bear
Editors' PickDec. 28, 2018 AGE, AMRN, CYDY87 Comments
Athersys: A Lucrative China Stem Cell Licensing Deal Seems Imminent
Dec. 9, 2018 ATHX150 Comments
An Interview With Athersys' CEO
Sep. 27, 2018 ATHX71 Comments
Mesoblast Signs Deal In China For Stem Cell Heart Therapies
Jul. 18, 2018 MESO7 Comments
Athersys/Healios Warrant Structure Bullish For Athersys Shares
Apr. 16, 2018 ATHX76 Comments
Athersys Gets $56 Million From Healios In Stem Cell Deal
Mar. 14, 2018 ATHX53 Comments
A Deep Drill Down To Walmart's Problem In E-Commerce
Feb. 21, 2018 WMT64 Comments
Athersys Poised For Lucrative Stem Cell Stroke Partnership This Year
May 16, 2017 ATHX115 Comments
BrainStorm Cell Therapeutics ALS Data Not As Promising As Press Releases Indicate
Editors' PickApr. 6, 2017 BCLI82 Comments
President Obama Signs 21st Century Cures Act - Implications For The Stem Cell Sector
Dec. 14, 2016 ATHX120 Comments
Marketplace Roundtable: The State Of Biotech
Editors' PickOct. 1, 2016 IBB, XBI44 Comments
All Systems Go On Athersys Pivotal Stem Cell Stroke Trial In Japan - Exploring The Scientific Evidence
Sep. 13, 2016 ATHX163 Comments
Brainstorm Cell Therapeutics: Caution Ahead Of ALS Phase II Data
Jun. 3, 2016 BCLI41 Comments
Stem Cell Company Athersys Firing On All Cylinders In 2016
Apr. 27, 2016 ATHX44 Comments
Cytori Cell Therapy Shows Promising Results In The Erectile Dysfunction Stem Cell Study
Feb. 4, 2016 PSTV15 Comments
Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again
Jan. 22, 2016 OCAT16 Comments
Top Stock Idea For 2016? - Athersys, A Beaten Down Stem Cell Stock With Great Upside
Jan. 20, 2016 ATHX114 Comments
Ocata Management Pulls Out All Stops To Push Astellas Merger Forward
Jan. 7, 2016 OCAT40 Comments
Stem Cell Company Cesca Therapeutics' Bad Idea
Nov. 17, 2015 THMO15 Comments
Astellas To Acquire Stem Cell Company Ocata Therapeutics At 90% Premium - What Does It Mean For The Stem Cell Sector?
Editors' PickNov. 12, 2015 OCAT52 Comments
WST Exclusive: Why Chugai And Athersys Parted Ways On Japan Stroke Stem Cell Program
Oct. 22, 2015 ATHX112 Comments